First uterine cancer test promises to corner multi-billion dollar market
This article was originally published in Clinica
In what could address a $2bn US market, US firm Cytocore has begun clinical trials for its uterine cancer screening test, that it says will "for the first time enable women at risk of uterine cancers and pre-cancers to be detected in their earliest stages".
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.